Skip to main content
Year archive

Oncopeptides — 2017 filings

All 35 regulatory filings released by Oncopeptides (ONCO) in 2017, sourced directly from the official regulator.

35 Filings
2017 Period
2017 filings (35)
Filing Released Lang
Oncopeptides presented survival data from the phase II-study O-12-M1 of Ygalo® (melflufen) at the 59th Annual Meeting of ASH today
AGM Information
2017-12-10 English
Oncopeptides presenterade idag överlevnadsdata från dess fas II-studie O-12-M1 med Ygalo® (melflufen) på ASHs 59:e årsmöte
Earnings Release FY 2017
2017-12-10 Swedish
Oncopeptides presented interim data from the ongoing phase II study HORIZON with Ygalo® (melflufen) at the 59th Annual Meeting of ASH today
Earnings Release FY 2017
2017-12-09 English
Oncopeptides presenterade idag interimsdata från den pågående fas II-studien HORIZON med Ygalo® (melflufen) på ASHs 59:e årsmöte
Earnings Release FY 2017
2017-12-09 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Q3 2017
2017-11-15 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Q3 2017
2017-11-15 English
Oncopeptides kommer att delta vid Jefferies Healthcare Conference i London den 16 november.
Regulatory Filings
2017-11-07 Swedish
Oncopeptides to attend the Jefferies Healthcare Conference in London on November 16th
Regulatory Filings
2017-11-07 English
Oncopeptides to present data from two clinical studies of Ygalo® (melflufen) at American Society of Hematology (ASH), December 9-12.
Investor Presentation
2017-11-01 English
Oncopeptides presenterar data från två kliniska studier med Ygalo® (melflufen) på ASH (American Society of Hematology) den 9-12 december.
Regulatory Filings
2017-11-01 Swedish
Valberedning utsedd inför årsstämma 2018 i Oncopeptides
Board/Management Information
2017-10-17 Swedish
Nomination Committee appointed in respect of AGM 2018 in Oncopeptides
AGM Information
2017-10-17 English
Interim / Quarterly Report 2017
Interim / Quarterly Report Q2 2017
2017-08-25 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Q2 2017
2017-08-25 English
First patient dosed in the pivotal phase III study OCEAN with Ygalo® (melflufen)
Regulatory Filings
2017-06-14 English
Första patienten har påbörjat behandling i den pivotala fas III studien OCEAN med Ygalo® (melflufen)
Regulatory Filings
2017-06-14 Swedish
BULLETIN FROM THE ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)
AGM Information
2017-05-18 English
KOMMUNIKÉ FRÅN ÅRSSTÄMMA I ONCOPEPTIDES AB (PUBL)
AGM Information
2017-05-18 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Q1 2017
2017-05-18 Swedish
Interim / Quarterly Report 2017
Interim / Quarterly Report Q1 2017
2017-05-18 English
Ändring av antalet aktier och röster i Oncopeptides AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2017-04-28 Swedish
Change in number of shares and votes in Oncopeptides AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2017-04-28 English
ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)
AGM Information
2017-04-18 English
ÅRSSTÄMMA I ONCOPEPTIDES AB (PUBL)
AGM Information
2017-04-18 Swedish
Oncopeptides AB emitterar 977 906 aktier ytterligare i samband med erbjudande om förvärv av aktier och notering på Nasdaq Stockholm (”Erbjudandet”)
Share Issue/Capital Change
2017-03-27 Swedish
ABG Sundal Collier AB utnyttjar övertilldelningsoption avseende 977 906 aktier i Oncopeptides AB (publ).
Share Issue/Capital Change
2017-03-24 Swedish
ABG Sundal Collier AB (”ABGSC”) har meddelat Oncopeptides AB (publ) (”Bolaget”) att stabiliseringsåtgärder avseende Bolagets aktier har vidtagits.
Capital/Financing Update
2017-03-22 Swedish
Additional patent protection for Ygalo granted in Europe until 2032
Regulatory Filings
2017-03-21 English
Ytterligare patentskydd för Ygalo har beviljas i Europa fram till 2032
Regulatory Filings
2017-03-21 Swedish
ABG Sundal Collier AB (”ABGSC”) har meddelat Oncopeptides AB (publ) (”Bolaget”) att stabiliseringsåtgärder avseende Bolagets aktier har vidtagits.
Share Issue/Capital Change
2017-03-13 Swedish
ABG Sundal Collier AB (”ABGSC”) har meddelat Oncopeptides AB (publ) att stabiliseringsåtgärder avseende Bolagets aktier har vidtagits.
Capital/Financing Update
2017-03-02 Swedish
Change in number of shares and votes in Oncopeptides AB (publ)
Share Issue/Capital Change
2017-02-28 English
Ändring av antalet aktier och röster i Oncopeptides AB (publ)
Declaration of Voting Results & Voting Rights Announcements
2017-02-28 Swedish
Bolagets vd förvärvar aktier i Oncopeptides
Director's Dealing
2017-02-24 Swedish
Company's CEO Acquires Shares in Oncopeptides
Director's Dealing
2017-02-24 English